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Objectives. The objective of this study was to determine the 
feasibility, safety and outcome of deferring angioplasty inpatients 
with angiographically intermediate l sions that are found not to 
limit flow, as determined by direct translesional hemodynamic 
assessment. 
Background. The clinical importance of some coronary stenoses 
of intermediate angiographic severity frequently requires nonin- 
vasive stress testing. Direct translesional pressure and flow 
measurements may assist in clinical decision making in patients 
with such stenoses. 
Methods. Translesionai spectral flow velocity (Doppler guide 
wire) and pressure data were obtained in 88 patients for 100 
lesions (26 single-vessel and 74 multivessel coronary artery le- 
sions) with quantitative angiographic oronary narrowings 
(mean -+ SD diameter narrowing 54 +- 7% [range 40% to 74%]). 
Target lesion angioplasty was prospectively deferred on the basis 
of predetermined normal values, defined as a proximal/distal 
velocity ratio <1.7 or a pressure gradient <25 mm Hg, or both. 
Patients were followed up for 9 -+ 5 months (range 6 to 30). 
Results. In the deferred angioplasty group, translesional veloc- 
ity ratios were similar to those of a normal reference group (mean 
1.1 -+ 0.32 vs. 1.3 -+ 0.55) and significantly ower than those of a 
reference cohort of patients who had undergone angioplasty 
(2.27 -+ 1.2, p < 0.05). The mean translesional pressure gradient 
in the deferred angioplasty group was also lower than that in the 
angioplasty group (10 _+ 9 vs. 45 -+ 22 mm Hg, p < 0.001). At 
follow-up in the deferred angioplasty group, four, six, zero and two 
patients, respectively, had had subsequent angioplasty, coronary 
artery bypass graft surgery or myocardial infarction or had died. 
In one patient, death was related to angioplasty of a nontarget 
artery lesion, and one patient with multivessel disease had a 
cardiac arrest due to ventricular fibrillation 12 months after 
lesion assessment. Among the 10 patients requiring later angio- 
plasty or coronary artery bypass grafting, only six procedures 
were performed on target arteries. No patient had a complication 
of translesional flow or pressure measurements. 
Conclusions. These data demonstrate he safety, feasibility and 
clinical outcome of deferring angioplasty of coronary artery 
narrowings associated with normal translesional coronary hemo- 
dynamic variables. Given the practice of performing angioplasty 
without ischemic testing or when testing is inconclusive, transle- 
sional hemodynamic data obtained at diagnostic atheterization 
can identify patients in whom it is safe to postpone angioplasty. 
(J Am Coll Cardiol 1995;25:178-87) 
Angiography is an imperfect method for determining the 
physiologic significance of coronary lumen narrowings, with 
significant interobserver and intraobserver variability > 15% in 
some studies (1-4). Recent reports using intracoronary ultra- 
sound imaging (5) have demonstrated the critical disparity 
between angiography and the presence, location and distribu- 
tion of coronary artery disease. Decisions regarding the need 
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for coronary interventions for myocardial ischemia should be 
based not only on clinical presentation a d angiographic lesion 
severity, but also on objective vidence of lesion-related isch- 
emia such as abnormal myocardial perfusion during stress 
testing with thallium perfusion scintigraphy (6,7), for example, 
or abnormal lesional hemodynamic measurements (8-10). In 
experimental nimal models, studies of coronary blood flow, 
coronary flow reserve and regional perfusion have demon- 
strated predictable r lations between anatomic and physiologic 
variables (8,10,11). However, in patients, imilar studies do not 
establish clinically reliable physiologic relations among quan- 
titative angiography (8,11), myocardial perfusion scintigraphy 
(12,13), coronary flow reserve (8,11,14,15) or translesional 
pressure gradients (16-19). Until recently, the clinical use of 
translesional pressure or flow measurements in patients has 
been limited primarily because the relatively large catheters 
interfered with the desired measurements, precluding this 
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methodology from becoming a routine component of either 
interventional or diagnostic angiography. Directly measured 
distal coronary blood flow velocity can now be easily and safely 
obtained by using a Doppler-tipped angioplasty guide wire 
(0.014 to 0.018 in. [0.036 to 0.046 cm] FloWire, Cardiometrics, 
Inc.) system with spectral velocity analysis capabilities at the 
time of diagnostic angiography (20). Measurement of transle- 
sional flow velocity has provided an additional physiologic 
objective on which to base a treatment decision (21). 
Thus, using translesional pressure and flow velocities mea- 
sured across coronary narrowings judged to be clinically and 
angiographically suitable for angioplasty, we proposed efer- 
ring coronary revascularization (angioplasty or coronary artery 
bypass grafting) until symptoms worsened and the target lesion 
progressed or new coronary lesions developed. We tested the 
hypothesis that the cardiac event rate in patients in whom 
angioplasty was deferred would be low and at least equal to or 
less than that for patients undergoing routine coronary angio- 
plasty. A secondary hypothesis tested was that coronary instru- 
mentation for pressure and flow velocity measurements could 
be performed with a complication rate <0.1%. This nonran- 
domized, observational pilot trial of a physiologic approach to 
decision making was undertaken prospectively to determine 
feasibility, safety and long-term clinical outcome in patients 
when angioplasty is deferred on the basis of normal transle- 
sional hemodynamics. 
Methods 
Study patients. Patients who were referred for diagnostic 
coronary angiography or angioplasty for typical clinical indica- 
tions, including evaluation of chest pain, exertional angina, 
postinfarction angina or follow-up of postangioplasty s mp- 
toms, were considered eligible for the study if there was at least 
one coronary artery narrowing with ->50% diameter narrowing 
by visual estimation i  the laboratory at the time of diagnostic 
study. For these lesions, decisions to perform angioplasty were 
based on clinical presentation, angiographic findings and trans- 
lesional pressure/flow criteria without review of stress test 
results. Patients with angina at rest, acute myocardial infarc- 
tion (onset <4 days before lesion evaluation), valvular disease, 
renal failure or congestive heart failure were excluded. Angio- 
graphic criteria for exclusion included collateral supply to the 
vessel under study, left main coronary artery narrowing (>40% 
diameter stenosis by visual assessment) and lesions that were 
inaccessible to the Doppler coronary guide wire. 
Anti-ischemic medications (nitrates, beta-adenergic block- 
ing agents and calcium channel antagonists) and antiplatelet 
agents were continued as clinically indicated. All patients 
received iazepam (2 to 4 mg intravenously) and diphenhydra- 
mine (25 mg intravenously) before the study. The study was 
approved by the Human Subjects Committee of the Institu- 
tional Review Board. Patients gave informed consent orally 
and in writing before the study. 
There were 197 patients tudied. The deferred angioplasty 
group comprised 88 patients: 26 with single-vessel and 62 with 
multivessel coronary artery disease. Nine of the 26 patients 
with single-vessel disease were evaluated for restenosis. Four- 
teen of the 62 patients with multivessel disease underwent 
angioplasty of a severe lesion in one vessel but only pressure- 
flow velocity assessment without angioplasty of the target 
lesion in another vessel. Flow velocity was also measured in58 
patients with angiographically normal coronary arteries under- 
going diagnostic study for a chest pain syndrome, cardiomyop- 
athy or valvular heart disease. Fifty-one patients with angio- 
graphically severe coronary artery lesions underwent 
translesional pressure-flow measurements before and after 
coronary angioplasty over the same study period. The data in 
these patients are reported as reference groups for event rate, 
safety and clinical outcome comparisons. 
Coronary angiography. Coronary angiography was per- 
formed from the femoral approach with 6F or 8F Judkins 
catheters in a routine manner after intracoronary (200 ~g) or 
sublingual (0.4 rag) nitroglycerin was given. In 90% of patients, 
orthogonal views of the lesion in question were obtained. Left 
ventriculography was performed in the 30 ° right anterior 
oblique projection. All patients received intravenous heparin 
(->5,000 U) before translesional hemodynamic assessment. 
Quantitative angiographic data analysis. Quantitative an- 
giography of the lesion or lesions of interest was performed by 
computer-assisted lectronic calipers (Sandhill, Inc.). The 
known diameter of the contrast-filled 6F (or 8F guiding) 
catheter was used as a reference standard. The lesion severity 
was then determined as percent diameter and area stenosis 
relative to the angiographically normal adjacent reference 
segment. The obstruction diameter (in ram) and area (in mm 2) 
were also obtained. In a subset of 28 patients, the computer- 
assisted caliper measurements were compared with results of 
digital analysis by using the Philips DCI automated coronary 
analysis (ACA) system (22). When orthogonal views of lesions 
could not be obtained (<10% of patients), the view with the 
most severe diameter narrowing was used. An angiographically 
significant stenosis was defined as ->50% diameter narrowing 
by visual assessment and post hoc ->40% diameter stenosis by 
quantitative coronary angiography (2,3,22). 
Coronary flow velocity measurements. Ten minutes after 
coronary angiography and nitroglycerin administration, trans- 
lesional flow velocity was measured with a 0.018-in. Doppler 
angioplasty guide wire (FloWire, Cardiometrics, Inc.) (Fig. 1). 
As described and validated by Doucette et al. (20), the 
Doppler angioplasty guide wire is a 175-em long, 0.018-in. 
diameter flexible, steerable guide wire with a 12-MHz piezo- 
electric ultrasound transducer integrated into the tip. The 
mechanical nd electrical characteristics of this guide wire are 
reported in detail elsewhere (20,23,24). The Doppler guide 
wire velocity demonstrated xcellent correlation with electro- 
magnetic flow velocity and volumetric flow in vitro and in vivo 
canine experimental models. The Doppler guide wire precisely 
measures phasic flow velocity patterns in small coronary 
arteries (20,23,24). 
The method of measuring translesional velocity has been 
previously described (20-24). In brief, after angiography, the 
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Figure 1. Instruments u ed in three methods ofassessing a coronary 
stenosis n the catheterization laboratory. Left, 8F coronary anglo- 
graphic atheter (Cordis). Center, 2.2F tracking catheter for measuring 
pressure gradients. Right, 0.018-in. Doppler-tipped angioplasty guide 
wire. 
Doppler guide wire was passed through astandard angioplasty 
Y-connector attached to either a 6F or 8F guiding catheter and 
then advanced into the target artery. Baseline flow velocity 
data were obtained at least 1 cm proximal to the lesion. The 
guide wire was then advanced 5 to 10 artery diameter lengths 
beyond the stenosis, avoiding placement in any small side 
branches, and distal flow velocity data were obtained. The 
velocity-pressure data correlations ofa subgroup of 33 patients 
with narrowings of intermediate angiographic severity have 
previously been published (21). Technical exclusions to flow 
velocity measurement comprised <10% of cases. Specific 
examples include angiograms demonstrating left main coro- 
nary artery narrowings >40% and highly tortuous, small 
(-<2.0-ram diameter) or diffusely diseased arteries. 
Translesional pressure gradient measurements. After the 
translesional flow velocity data were recorded, a 2.7F infusion 
catheter (Tracker 18, Target Therapeutics) was then advanced 
over the guide wire beyond the stenosis into the distal portion 
of the coronary artery. The guide wire was removed and the 
guiding and infusion catheters were flushed. Phasic and mean 
pressures in the distal arterial segment were recorded simul- 
taneously with aortic pressure measured at the ostium of the 
guiding catheter with the use of fluid-filled tubing and standard 
transducers (Namic, Inc.). The infusion catheter was then 
withdrawn to the proximal location while pressure was contin- 
uously recorded to obtain the intrinsic pressure difference 
between the guiding and infusion catheters. In general, the 
intrinsic pressure gradients of this catheter system were 
<5 mm Hg. The translesional pressure gradient was defined as 
(Mean guiding catheter pressure - Mean distal coronary 
artery pressure) - Any intrinsic catheter-induced gradient. 
Coronary flow reserve. In 111 patients (including 65 pa- 
tients in the deferred angioplasty group), after baseline distal 
arterial flow velocity data were obtained, intracoronary aden- 
osine (6 to 8/xg in the right coronary artery and 12 to 18/zg in 
the left coronary artery) (25) was administered and a second 
set of velocity indexes was obtained at peak maximal hyper- 
emia. Post-stenotic coronary flow reserve was computed as the 
quotient of hyperemic/basal average peak velocity (26,27). 
Coronary flow velocity signal analysis. Translesional f ow 
velocity data were recorded on a video page printer. The peak 
diastolic and systolic velocities, diastolic and systolic velocity 
integrals (obtained by computer planimetry of the total area 
under the peak instantaneous velocity profile), average peak 
velocity and the total velocity integral were automatically 
derived. This method was previously validated with the use of 
a custom software program and manual tracing of the spectral 
peak Doppler velocity signal on a digital computer bit pad 
(23,24). The ratio of proximal to distal velocity employed both 
the average peak velocity and the total velocity integral. 
Criteria for normal translesional hemodynamic variables. 
Criteria for normal translesional flow velocity were based on 
obtaining at least two of the following three variables: 1) 
proximal/distal total integral or average flow ratio < 1.7 (21); 2) 
diastolic/systolic velocity (single beat) ratio >1.4 (23); 3) 
normal distal coronary vasodilator reserve, defined as hypere- 
mia/basal mean flow ratio >2.0 (24). In a previous tudy (21), 
a proximal/distal f ow velocity ratio was not found to be 
reliable when there was an ostial lesion, diffuse distal disease, 
tandem or serial lesions or a nonbranched conduit (e.g., 
saphenous vein graft or internal mammary artery). These flow 
criteria were selected to identify hemodynamically significant 
lumen narrowings (i.e., translesional gradients >20 to 
30 mm Hg) based on previous angioplasty studies (16-19,28). 
Patients with conditions that limited ability to obtain an 
accurate translesional velocity ratio, such as serial lesions in 
the same vessel, diffuse distal disease or nonbranching conduits 
(saphenous vein graft, internal mammary artery), were in- 
cluded only if a translesional pressure gradient <20 mm Hg 
was present (28) (Fig. 2). 
Clinical follow-up. In patients having exercise or pharma- 
cologic (dipyridamole or adenosine) radionuclide stress tests, 
the data acquisition was performed in a standard fashion, as 
previously reported (13,29,30). Clinical follow-up was obtained 
by letter and by telephone contact with the patient, family or 
the patient's physician, alone or in combination. Clinical events 
were defined as 1) coronary artery bypass grafting; 2) coronary 
angioplasty; 3) myocardial infarction as identified from hospi- 
tal records, standard electrocardiography and elevation of 
cardiac isoenzymes; or 4) death. Symptoms were presumed to 
be unchanged unless the patient was readmitted tothe hospital 
because of cardiovascular complaints. 
Statistical analysis, Translesional f ow velocity variables 
and pressure gradients among roups were compared by using 
analysis of variance and the Scheff6 test for differences of the 
means. Comparison of quantitative angiographic data between 
the deferred angioplasty and angioplasty groups was per- 
formed with the unpaired Student two-tailed t test. Actuarial 
event-free rates were analyzed by using the Kaplan-Meier 
survival statistical analysis on SPSS PC + Advanced Statistics 
Version 4.0. Differences in event-rates were calculated by using 
the log-rank statistic over the duration of the follow-up period 
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Figure 2. A, Cineangiographic frames 
of an eccentric lesion in the left ante- 
rior descending coronary artery in a 
59-year old man with chest pain and 
equivocal radionuclide stress test. In 
the left anterior oblique (LAO) view, 
the lesion is severe (>80%). In the 
right anterior oblique (RAO) view, the 
lesion is moderate (<50%). B, Same 
patient. Flow velocity spectra (top 
panels) and translesional gradients 
(lower panels). Measurements were 
made at rest and during maximal hyper- 
emia with adenosine (12 txg intracoro- 
nary [IC]). Proximal and distal flow 
velocities are nearly identical, with a 
normal phasic pattern and proximal/ 
distal ratio of 1.05. The rest gradient is 
zero. With adenosine, distal flow in- 
creases 2.5 times that at baseline, and 
the hyperemic gradient is 10 mm Hg. 
No angioplasty was performed. The 
patient's symptoms abated, and he has 
been well after 18 months of follow- 
up. Ao + COR = aortic plus coronary 
artery pressure; ECG = electrocardio- 
gram. Modified, with permission, from 
Donohue et al. (21). 
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(31). A chi-square contingency analysis was also used to 
compare frequency of events between groups. Statistical sig- 
nificance was accepted at p < 0.05. Data are presented as mean 
value _+ 1 SD unless otherwise indicated. 
Results 
The clinical characteristics of the study groups are shown in 
Table 1. Compared to patients with angiographic oronary 
artery disease, the group with normal coronary arteries had 
more women, and a lower mean cholesterol evel, fewer 
cardiovascular symptoms, less hypertension and a smaller 
proportion of patients with a smoking history. There were no 
significant clinical differences between the deferred angio- 
plasty and angioplasty groups. 
Quantitative angiography (Table 2). There was a similar 
distribution of target arteries studied. In the three groups 
(normal arteries, deferred angioplasty and angioplasty), mea- 
surements were made, respectively, in the left anterior de- 
scending coronary artery in 36%, 39% and 33%; the right 
coronary artery in 19%, 27% and 33%, and the left circumflex 
artery in 28%, 28% and 24% of cases. By quantitative post hoc 
analysis of the target vessel lesion, the percent lumen area 
reduction, percent diameter stenosis and obstruction diameter 
in the deferred angioplasty group were 77 _+ 8%, 54 _+ 7% and 
1.32 + 0.33 mm, respectively. These values indicated less 
severe disease than that indicated by the values in patients 
undergoing coronary angioplasty (93 +_ 7%, 84 -+ 11%, 0.6 _+ 
0.36 ram, respectively; all p < 0.05). There were no significant 
differences in the arterial diameters used as the normal 
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Table 1. Clinical Data for the Three Patient Groups 
Angiographically Deferred 
Normal Arteries Angioplasty Angioplasty 
Patients tudied 58 88 51 
Arteries studied 86 100 51 
Male patients 34 (58.6%)* 66 (75.0%) 34 (66.7%) 
Age (yr) 60 _+ 12 60 -+ 11 58 _+ 13 
Elevated cholesterol (>220 mg/dl) 21 (36.2%)* 54 (61.3%) 24 (47.1%) 
Left ventricular hypertrophy 3 (5.2%) 3 (3.4%) 1 (2.0%) 
Unstable angina 20 (34.5%)* 53 (60.2%) 40 (78.5%) 
Myocardial infarction 10 (17.2%)* 28 (31.8%) 22 (43.1%) 
Hypertension 33 (56.9%)* 61 (69.3%) 31 (60.8%) 
Diabetes mellitus 8 (13.8%) 22 (25%) 8 (15.7%) 
Current smoker 12 (20.7%)* 27 (30.6%) 22 (43.1%) 
Previous moker 5 (8.6%)* 17 (19.3%) 9 (17.7%) 
History of angioplasty 8 (13.8%)* 31 (35.2%) 21 (41.2%) 
History of CABG 6 (10.3%) 9 (10.2%) 7 (13.7%) 
Postmenopause 22 (37.9%) 19 (21.5%) 11 (21.6%) 
Obesity 9 (15.5%) 10 (11.3%) 7 (13.7%) 
Family history 20 (34.5%)* 49 (56.3%) 30 (58.8%) 
Medications 
Aspirin 21 (36.2%)* 66 (75.8%) 40 (78.4%) 
Calcium channel blocker 21 (36.2%) 64 (74.4%) 28 (49.5%) 
Nitrates 20 (34.5%) 51 (58.6%) 29 (56.9%) 
Dipyridamnle 5 (8.6%) 3 (3.5%) 3 (5.8%) 
Beta-adrenergic blocking agent 12 (20.7%) 22 (25.3%) 15 (29.2%) 
*p < 0.05 normal versus deferred angioplasty group. Data are presented as number (%) of patients. CABG - 
coronary artery bypass graft surgery. 
re ference segments.  In a matched compar i son  of  angiographic  
techn iques  in 28 pat ients,  cal iper quant i tat ive measurements  of 
stenosis d iameter  overest imated  the Phi l ips DCI -ACA quan-  
t itative analysis by a mean of 9 _+ 20%. 
Translesional pressure, flow velocity and coronary vasodi- 
lator reserve data (Table 2). Accord ing  to the study design, 
t rans les ional  pressure gradients  were lower for the defer red 
angioplasty than  for the angioplasty group (10 _+ 9 vs. 46 _+ 
Table 2. Angiographic and Translesional Hemodynamic Data 
Angiographically Deferred 
Normal Arteries Angioplasly Angioplasty 
Angiographic findings 
Coronary artery studied 
Left anterior descending 21 (36.2%) 39 (39%) 17 (33.3%) 
Right 11 (18.9%) 27 (27%) 17 (33.3%) 
Left circumflex 16 (27.6%) 28 (28%) 12 (23.5%) 
Left main 5 (8.6%) 0 0 
Diagonal 2 (2.3%) 4 (4%) 1 (1.9%) 
Graft 3 (3.5%) 1 (1.1%) 4 (7.8%) 
Internal mammary 3 (3.5%) 1 (l. 1%) 0 
Reference artery diameter (mm) 2.96 _+ 0.47 2.9 _+ 0.63 2.8 _+ 0.70 
QCA % diameter - -  54 _+ 7 84 +_ 11' 
QCA % area stenosis - -  77 _+ 8 93 _+ 7* 
Obstruction diameter (mm) - -  1.3 + 0.33 0.6 -+ 0.36* 
Flow velocity datat Preangioplasty 
Proximal/distal velocity integral ratio 1.1 _+ 0.32 1.3 _+ 0.55 2.27 _+ 1.2" 
Diastolic/systolic velocity ratio 1.74 _+ 0.79 1.8 _+ 0.58 1.26 _+ 0.40* 
Mean velocity (cm/s) 22.4 _+ 11.5 26.4 _+ 11.8 17.4 _+ 9.3* 
Mean velocity, hyperemia (cm/s) 47.1 _+ 15.9 48.5 _+ 15.7 24.4 _+ 13.5" 
Coronary vasodilatory eserve 2.3 _+ 0.6 2.0 _+ 0.64 1.36 _+ 0.4* 
Pressure gradient (ram Hg) - -  10.1 _+ 8.8 45.5 _+ 21.7" 
*p < 0.05 versus other groups, tAll measurements are distal to lesion, except proximal/distal ratio. Data are 
presented as number (%) of patients or mean value - SD. QCA - quantitative coronary angiography. 
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Figure 3. A, Quantitative coronary angiographic percent diameter 
stenosis correlation with proximal/distal (P/D) flow velocity ratio. 
B, Translesional pressure gradient correlation with proximal/distal 
velocity ratio. C, Translesional pressure gradient correlations with 
distal coronary flow reserve (CFR). 
22 mm Hg, p < 0.01). Proximal/distal velocity ratios demon- 
strated similar values for both the normal and deferred angio- 
plasty groups with significant differences from values in the 
angioplasty group (normal 1.1 + 0.32, deferred angioplasty 
1.3 _+ 0.55, angioplasty 2.3 _+ 1.2; p < 0.05 vs. both normal and 
deferred angioplasty groups). All patients in the angioplasty 
group had a successful procedure with a residual stenosis 22 + 
14% in diameter, postprocedure proximal/distal velocity ratio 
1.7 _+ 1.5 and translesional pressure gradient 14 +_ 7 mm Hg. 
The correlations of the percent stenosis with proximal/distal 
velocity ratios, and correlations of translesional pressure gra- 
dients with proximal/distal velocity ratios and coronary flow 
reserve are provided in Figure 3. By post hoc quantitative 
coronary angiographic analysis, 18 target lesions assessed 
visually as >50% were measured as ->40% and -<49% by 
quantitative coronary angiography (Fig. 3A). In two patients, 
the proximal/distal ratio was >3 with corresponding pressure 
gradients of 10 mm Hg (Fig. 3B). In 14 of 16 patients with 
coronary vasodilator reserve <2.0, translesional pressure gra- 
dients were <20 mm Hg (Fig. 3C). 
Clinical outcomes and events (Tables 3 to 5). Clinical 
follow-up data were available in 55 (95%) of 58, 84 (95%) of 
Table 3. Clinical Follow-Up Data 
Angiographically Deferred 
Normal Arteries Angioplasty Angioplasty 
Patients with clinical follow-up 55 (95%) 84 (95%) 45 (88%) 
Repeat hospital admission 10 (17.2%) 18 (21.4%) 17 (37.8%) 
Cardiac events 
Coronary angioplasty 1 (2.7%) 4 (4.7%) 6 (13.3%) 
Coronary artery bypass graft 0 6 (6.9%) 6 (13.3%) 
Myocardial infarction 0 0 0 
Death 2 (5.4%) 2 (2.3%) 1 (2.2%) 
Noncardiac events 8 (14.5%) 3 (3.5%) 4 (8.9%) 
Unable to contact 3 (5.2%) 1 (1.2%) 6 (13.3%) 
Months to follow-up 
Mean 9.8 _+ 8.5 8.6 + 4.7 7.1 _+ 5.0 
Range 2 to 31 6 to 30 1 to 24 
Days to stress test 
Mean 27.7 _+ 101.3 28.4 _+ 63.3 36.3 +_ 49 
Range* -57 to 369 -120 to 360 -37 to 158 
*Days before procedure indicated by (-).  Data are presented asnumber (%) 
of patients or mean value + SD. 
88, and 45 (88%) of 51 patients for the normal artery, deferred 
angioplasty and angioplasty groups, respectively, with a similar 
mean time to follow-up (10 _+ 9, 9 -+ 5 and 7 _ 5 months, 
respectively). In the deferred angioplasty group, the minimal 
follow-up period was 6 months (range 6 to 30). 
In the deferred angioplasty group, 18 patients were read- 
mitted to the hospital for noncardiac or anginalike symptoms; 
12 of these patients had a cardiac event. No patient had a 
myocardial infarction. One patient died of complications after 
angioplasty of a nontarget artery. One patient with multivessel 
coronary artery disease and decreased left ventricular function 
died suddenly of ventricular fibrillation 12 months after lesion 
assessment. Seven patients underwent repeat coronary angiog- 
raphy without apparent angiographic hange in the target 
lesions. In these patients, the attending physician deemed 
intervention unnecessary on the basis of negative stress testing 
results. Ten patients required either coronary artery bypass 
grafting (n = 6) or coronary angioplasty (n = 4); only six of the 
procedures involved target arteries (Tables 4 and 5). Angio- 
graphic lesion progression and conversion to abnormal trans- 
lesional hemodynamics occurred in four of six target arteries. 
Two patients underwent angioplasty for symptoms despite no 
change in flow or angiographic findings (Table 5). Among the 
six patients who required bypass urgery, only three operations 
involved a target artery with previously normal translesional 
flow velocity. The distribution of these events in patients with 
single and multivessel disease is shown in Table 4. 
The cumulative rate analysis of events demonstrated no
difference in time to coronary artery bypass urgery or angio- 
plasty between deferred angioplasty subgroups with single or 
multivessel disease, although the total event rate was low. 
Safety. There were no complications related to transle- 
sional pressure or flow velocity measurements in any of the 197 
patients tudied. 
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Table 4. Clinical Outcome of Deferred Angioplasty 
No. of Repeat Hospital Catheterization 
Patients Admission Angioplasty CABG Only 
One-vessel disease 26 4 2* 1 1 
Multivessel disease 
Two-vessel 26 8t 1 3 (l other area)$ 3 
Three-vessel 22 5 1 (other area):]: 2 (2 other areas)~: 1 
Three-vessel§ 14 I t -- -- -- 
Total 88 18 4 6 5 
*Angioplasty with normal translesional flow. tOne death, tOther area remote from target artery with velocity 
measurement. §Significant lesions in all three major arteries as well as in a large diagonal or a large obtuse marginal 
branch, or both. CABG = coronary artery bypass graft surgery. 
Discuss ion  
The major findings of this study demonstrate that in 
patients with lesions of intermediate angiographic severity, 
normal translesional hemodynamic data can be acquired safely 
and angioplasty can be deferred with -92% of target arteries 
evaluated remaining stable without the need for intervention. 
No patient died or developed acute myocardial infarction or 
unstable angina as a result of progression of a target artery 
lesion. By visual angiographic and clinical criteria, a majority of 
these lesions would have been scheduled for dilation, many 
without any physiologic assessment of lesion significance by 
methods uch as ischemic stress testing. A recent retrospective 
review of the practice of angioplasty in the United States 
indicates that in >60% of patients, no objective evidence of 
myocardial ischemia was obtained before coronary interven- 
tions were performed (32). 
The use of translesional hemodynamic data to assist the 
clinical decision for intervention represents a departure from 
current interventional cardiology practice. In-laboratory phys- 
iologic assessment may be especially important when ischemic 
stress testing has not or cannot be performed or has yielded 
equivocal results. This approach may also assist in selecting 
hemodynamically significant lesions in the routine practice of 
multivessel, multilesion angioplasty in which not only the 
assumed culprit lesion is treated, but also other angiographi- 
cally significant lesions are often dilated without additional 
assessment. 
Translesional hemodynamic variables and angiography. 
Previous studies in our laboratory (21) indicate that within 
branching coronary circulations, translesional flow velocity 
ratios < 1.7 are associated with translesional pressure gradients 
<30 mm Hg. Although the precise minimal translesional 
pressure gradient requiring intervention has not been deter- 
mined, translesional gradients ->30 mm Hg have been associ- 
ated with positive ischemic test results (17,19) and poor 
long-term postangioplasty results (16-18,28). The majority of 
patients in this study had coronary lesions of intermediate 
severity by quantitative coronary angiography. However, in the 
post hoc analysis, 18 patients had quantitative coronary angio- 
graphic diameter stenosis <50%. The disparity between visual 
estimation of lesion severity and quantitative coronary angiog- 
raphy is well recognized. A precise application of quantitative 
coronary angiographic riteria may have been sufficient to 
define some lesions as nonsignificant; however, these patients 
were included as part of the spectrum of lesions that are 
encountered and would be evaluated and potentially treated in 
clinical practice. The proportion of events remains unchanged 
when these patients are excluded. 
Post-stenotic flow velocity reserve. A coronary vasodilator 
value >2.0 was selected as a lower limit of normal because of 
the correlation between ormal myocardial thallium scintigra- 
phy and coronary vasodilator reserve values >2.0 (33). In a 
recent study comparing post-stenotic flow reserve with myo- 
cardial perfusion scintigraphy data (33), negative ischemic 
Table 5. Follow-Up Data in Patients With Flow-Normal Target Arteries Requiring Revascularization 
% Stenosis Diameter* 
Pt Target Conversion toAbnormal Time to Reason for 
No. Artery lnitial Fol low-Up Translesional Flow Velocity Stress Test  Angioplasty (mo) Angioplasty/CABG 
1 RCA 50 72 Yes Not done 2 Symptoms 
2 RCA 45 83 Yes + 9 Symptoms 
3 RCA 60 60 No + 1 Symptoms 
4 LAD 60 85 Yes + 3 Symptoms 
5 RCA 60 89 Yes - 5 Symptoms 
6 LCx 40 40 No + 1 Symptoms + ETI" 
*As assessed byquantitative coronary angiography. CABG - coronary artery bypass graft surgery; ETr = exercise treadmill test results; LAD = left anterior 
descending coronary artery; LCx left circumflex coronary artery; RCA = right coronary artery; - = negative; +- positive. 
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stress test results were associated with normal translesional 
flow dynamics in 92% of patients. In addition, abnormal 
radionuclide stress cintigraphic findings were associated with 
low translesional gradients (<20 mm Hg) and normal rest 
translesional flow velocity in 32% of cases, and with abnormal 
coronary vasodilator reserve (<2.0) in 28%. Twelve of 16 
patients with coronary vasodilator reserve <2.0 had a transle- 
sional gradient <20 mm Hg (Fig. 3), suggesting that impaired 
myocardial microvascular responses were also present. Al- 
though normal coronary vasodilator reserve >3.5 has been 
reported by others, normal coronary vasodilator reserve in our 
laboratory and in others has been lower (2.5 to 3.0) because of 
the unselected nature of patients with angiographically normal 
arteries undergoing catheterization. 
Clinical outcome of patients in the angioplasty and de- 
ferred angioplasty groups. The angioplasty and deferred an- 
gioplasty groups differed in the biologic severity of the coro- 
nary lesions. It could be postulated that the event rate in the 
group whose angioplasty was deferred on the basis of interme- 
diate lesion severity should be lower than that of a group with 
more severe lesions. The angioplasty group was used to 
compare the rates of repeat hospital admission and repeat 
revascularization that occurred with routine angioplasty with 
those that occurred in patients who had instrumented lesions 
suitable for angioplasty but in whom the procedure was 
deferred. The proportion of patients who underwent repeat 
hospital admission, repeat coronary angioplasty or coronary 
artery bypass graft surgery was greater in the angioplasty than 
in the deferred angioplasty group. In the latter group, 4 of the 
10 clinical events were related to lesion progression in coro- 
nary arteries that did not undergo flow assessment. Although 
event rates were higher for patients with multivessel disease, 
the results were statiscally similar for the subgroups with single 
and multivessel disease, probably because of the low overall 
number of events. The event rate in the deferred angioplasty 
group was lower than that reported by Parisi et al. (34) in 
patients with single-vessel disease randomized to medical 
therapy or angioplasty. It can be conjectured that he low event 
rate in such patients in both studies may be due, in part, to 
minimally disturbed translesional physiology, which may not be 
improved by an angiographically cosmetic angioplasty procedure. 
Symptoms appeared to be adequately controlled in >90% 
of patients in the deferred angioplasty group. Anginalike 
symptoms may be due to causes other than epicardial coronary 
artery disease. Severe anginalike syndromes without specific 
ischemic electrocardiographic changes are commonly reported 
in patients with angiographically normal coronary anterio- 
grams (35). Given the immediate and long-term risks of 
revascularization by angioplasty, objective evidence of isch- 
emia should be required before coronary lesions are dilated in 
the absence of unstable ischemic syndromes (9). 
Safety and cost. Translesional hemodynamic instrumenta- 
tion required 20 to 30 rain and cost -$500 for the Doppler- 
tipped angioplasty guide wire and pressure catheter. The safety 
of Doppler guide wire instrumentation in both normal and 
diseased arteries in this study was excellent. In >10,000 uses of 
this Doppler guide wire worldwide, <10 incidents of guide 
wire-related coronary artery injury were reported to the Food 
and Drug Administration. 
Limitations of the study. This study was a nonrandomized, 
prospective observational study with the well known inherent 
design limitations of such studies. Because of the unique ap- 
proach to decision making, afeasibility and safety pilot study was 
needed before proposing a large, multicenter randomized trial. 
The technical imitations of obtaining satisfactory flow 
velocity signals have been described elsewhere (20-24). The 
flow velocity signal was accepted after guide wire manipulation 
to identify an optimal Doppler signal. Anatomic and technical 
limitations may cause distal flow velocities to be underesti- 
mated, producing an error in favor of intervention. Conversely, 
a guide wire positioned in a location with multiple or diffuse 
distal arterial narrowings might sample a region of high 
velocity and produce afalsely elevated istal flow velocity and 
near-normalized flow ratio indicating an insignificant lesion. In 
patients with serial lesions, recognizable diffuse distal disease 
or conditions adversely influencing a proximal/distal flow ve- 
locity ratio, translesional pressure gradients were measured. 
Coronary vasodilator reserve values in both the normal and 
the deferred angioplasty groups were, on average, <3.0, the 
lower limit of normal reported in previous animal (10) and 
selected patient studies (14,25) using Doppler catheters in 
regions proximal to the stenoses in question. Our laboratory 
and others (21,23,35) have found lower ranges of coronary 
vasodilator reserve in angiographically normal arteries related 
to coexistent conditions that are associated with microcircula- 
tory impairment. Although collateral f ow may rarely confound 
distal flow velocity interpretation (36), no patient had anglo- 
graphic or Doppler evidence of collateral flow to the target 
artery. 
A translesional pressure gradient >25 mm Hg was empir- 
ically determined to be the initial range at which distal 
coronary flow velocity became impaired relative to proximal 
values in branching systems (21). The pressure gradient criteria 
used in this study were derived from postangioplasty transle- 
sional pressure gradients <20 mm Hg that were often accepted 
as a satisfactory procedural result. 
Guide wire- and catheter-induced artifacts. Translesional 
pressure measurements may be affected by a tracking catheter 
across the arterial stenosis, atechnical limitation that could be 
overcome by using a tip-mounted microsensor pressure guide 
wire (37-39). For flow velocity, the small cross-sectional rea 
of the Doppler-tipped guide wire (0.16 mm 2) is <10% of the 
residual cross-sectional rea of a 2.5-ram diameter (4.9 mm 2) 
vessel that has a 60% diameter stenosis (1.8 mm2). A system- 
atic error produced by the additional cross-sectional rea of 
the larger pressure gradient catheter would overestimate the 
translesional hemodynamic findings, thereby favoring interven- 
tion. A lower pressure gradient criterion might prove superior 
when using a pressure guide wire, unavailable at the time of 
this study. 
Rest translesional hemodynamic data may not reflect dy- 
namic ischemia-producing conditions such as exercise or emo- 
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tional stimuli potentially associated with coronary vasocon- 
striction or increased myocardial blood flow demands, or both 
(40-42), conditions readily responsive to medical therapy. 
Angioplasty enlargement of the epicardial artery lumen may 
not improve distal flow, especially for lesions with normal rest 
and hyperemic flow and pressure gradients. Medical therapy to 
limit episodic reduction of coronary flow may account for the 
clinical improvement or stabilization of symptoms in the 
deferred angioplasty group in this and similar studies (34). In 
view of the small sample size and low event rates, larger 
prospective randomized subgroup studies will be needed to 
provide definitive outcome data. 
Clinical significance. This study addressed the safety and 
clinical outcome of deferring angioplasty based on normal 
translesional pressure/flow velocity data as an adjunct to 
angiography in clinical decision making. These findings indi- 
cate that employing physiologic measurements in conjunction 
with angiography is safe and may be clinically useful. Transle- 
sional flow velocity-pressure m asurements can provide objec- 
tive functional evidence of lesion significance to assist in 
selecting patients for appropriate coronary interventions. 
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